查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864112

癌症疼痛管理市场按药物类别、给药途径、通路、最终用户和应用划分－2025-2032年全球预测

Cancer Pain Management Market by Drug Class, Route Of Administration, Distribution Channel, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，癌症疼痛管理市场将成长至 128.1 亿美元，复合年增长率为 6.29%。

关键市场统计数据
基准年 2024 78.6亿美元
预计年份：2025年 83.5亿美元
预测年份 2032 128.1亿美元
复合年增长率 (%) 6.29%

本书全面介绍了癌症疼痛管理，系统地说明了临床复杂性、跨学科护理以及医疗保健系统各相关人员的策略重点。

癌症疼痛管理处于肿瘤治疗、安宁疗护和医疗保健系统经济学的关键交汇点。肿瘤学的进步延长了许多患者的生存期，因此，对能够维持患者功能和生活品质的细緻入微且持续的疼痛管理方法的需求也日益增长。临床医生现在必须平衡急性手术疼痛、慢性癌症相关疼痛综合症和复杂的神经病变疼痛，以及合併症、多重用药和患者多样化的偏好。因此，疼痛管理策略必须具有适应性、实证性，并与不断发展的护理标准保持一致。

在所有医疗机构中，迫切需要提供有针对性的疼痛缓解方案，同时最大限度地减少副作用和成瘾风险。这需要将药物治疗方案（例如辅助镇痛药、局部麻醉剂、非类固醇消炎剂和鸦片类药物治疗）与非药物疗法和介入技术结合。法律规范、公共卫生部门关于阿片类药物管理的优先事项以及支付方政策正在重塑医疗服务提供者的决策。此外，以患者为中心的模式，包括共用决策和结果评估，正开始在定义治疗选择的价值方面发挥核心作用。

鑑于癌症相关疼痛治疗的复杂性，相关人员需要临床严谨的指南，该指导应整合治疗方法、给药途径、分销动态和最终用户需求。本执行摘要总结了针对临床领导者、产品负责人和医疗系统在快速变化的癌症相关疼痛治疗领域中所需的策略见解和实用建议。

临床个体化、阿片类药物管理、新型给药技术以及支付主导的疗效评估如何重塑整个治疗路径中的癌症疼痛管理

癌症疼痛管理领域正经历多项变革，这些变革正共同重塑临床实务和商业策略。首先，疼痛亚型表型分析的进展以及对神经病变疼痛和伤害性疼痛机制更深入的理解，正推动着镇痛治疗方案向个体化方向的显着转变。这种转变促使临床医师根据疼痛病因和患者的具体风险因子来选择治疗方法，而不是采用千篇一律的治疗方案。

同时，阿片类药物管理倡议和加强处方监测正在加速推广多方面综合治疗方法，强调辅助性镇痛药、局部麻醉技术和标靶非阿片类药物治疗。这些变化，加上新型给药平台和经皮系统的出现（这些系统能够提高患者依从性并最大限度地减少全身暴露），正在推动进一步的进展。数位疗法、远端监测和远端医疗透过持续评估疼痛、副作用和患者报告的疗效，进一步改变了治疗路径，从而支持更快地调整治疗方案。

在商业层面，供应链韧性以及专科药局、医院采购团队和製造商之间的策略联盟正在重塑流通结构。支付者越来越关注疗效和成本控制，新的合约模式正在实施，这些模式奖励功能性疗效的改善和住院次数的减少。总而言之，这些变化要求建立适应性临床通讯协定，投资于数据驱动的监测，并进行协作式政策制定，以确保患者获得有效、安全且可近的疼痛治疗。

评估2025年美国关税对癌症疼痛药物供应和取得的多方面营运和采购影响

2025年实施的政策和贸易措施为癌症止痛药物的采购、定价行为和供应链规划带来了新的动态动态。影响进口原料药和成品药的关税调整增加了製造商和医疗保健系统采购决策的复杂性。许多相关人员正在透过重新评估其供应商组合併加快生产和原材料采购多元化策略来应对这些变化，以降低关税带来的成本压力。

对于负责药品清单和采购的医院系统和药房网络而言，这些因素累积作用，使得他们更加关注医疗总成本。采购团队正在协商长期供应协议，寻求合约保障以应对价格波动，并优先考虑具备垂直整合能力的供应商。同时，一些製造商正在评估国内或区域性生产方案以及策略联盟，以维持市场进入并降低未来贸易不确定性的风险。

这些趋势进一步凸显了基本契约的重要性，此类协议强调基于可衡量的临床结果的透明定价和支付结构。临床医生和药房负责人正在积极应对，他们强调能够体现成本效益的临床路径，在临床适宜的情况下推广替代治疗方法，并与支付方合作，确保最需要的患者能够持续获得治疗。最终，在价格敏感的环境下，维持癌症疼痛药物的可靠供应需要持续的政策监督和积极主动的供应链策略。

透过详细的細項分析，揭示了产品定位、临床路径匹配以及按药物类别、给药途径、分销管道、用户和应用分類的分销差异。

基于细分市场的分析揭示了不同药物类别、给药途径、分销管道、终端用户环境和应用需求的显着临床和商业性趋势。药物类别涵盖辅助镇痛药、局部麻醉剂、非类固醇消炎剂和鸦片类药物。在辅助性止痛药中，抗惊厥药、抗忧郁症和皮质类固醇等特定亚类药物针对癌症疼痛的神经病变和发炎性成分。同时，阿片类药物进一步分为天然、半合成和合成製剂，它们具有不同的受体谱、安全性考量和法律规范。

给药途径也是区分不同疗法的关键因素，口服、肠外、舌下和经皮给药方式影响临床应用。口服疗法（通常以胶囊、溶液或片剂形式给药）仍然是慢性门诊治疗的主要手段，而肠外製剂（肌肉注射、静脉注射或皮下注射）对于急性期、手术和住院至关重要。舌下给药方式（包括薄膜和含片）起效迅速，方便缓解突发性疼痛，而经皮系统则能持续给药，并在某些患者群体中具有更高的依从性。

通路的特性会影响患者透过医院、线上和零售药房等管道获得药品的可近性和就医体验。每个管道在采购、配药和管理流程方面都有其独特的流程。最终使用者群体涵盖肿瘤中心、居家医疗机构和医院，其临床专科、监测能力和资源投入程度各不相同。此外，特定应用场景下的疼痛，例如骨转移疼痛、神经病变疼痛和内臟疼痛，需要个人化的疼痛管理策略和诊疗路径。这些细分观点指导产品定位、临床指南制定以及与目标相关人员的沟通，以满足不同的临床需求和实际运作。

区域性进入模式、处方习惯和供应链影响分析（美洲、欧洲、中东和非洲、亚太地区）

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的医疗服务取得模式、治疗方法偏好和相关人员的优先事项有显着影响。在美洲，整合的医疗体系和强大的专科药房基础促使新型配药平台和病患援助计画得以快速推广，而监管机构对鸦片类药物安全性的关注也持续影响着处方实践和管理措施。相较之下，欧洲、中东和非洲的支付方结构和采购模式各不相同，部分市场实行集中竞标，且该地区的药品目录和安宁疗护基础设施也存在显着差异。

亚太地区各市场的基础设施成熟度存在显着差异，一些都市区已实施先进的多模式疼痛管理方案和远端医疗随访，而另一些地区则面临服务分散和供应链受限的问题。在所有地区，人口结构变化和生存率的提高都在推动对以患者为中心的可持续疼痛管理解决方案的需求，但服务获取途径因报销模式、当地监管重点以及社区医疗与医院医疗的普及程度而异。

随着我们从区域具体情况转向营运影响，相关人员必须使其临床教育、经销伙伴和循证策略与区域支付方的期望和法规结构保持一致。透过将产品材料和价值提案与区域特定的医疗模式和采购机制相匹配，製造商和医疗系统可以更有效地支持各区域独特环境下的临床医生和患者。

主要企业如何透过研发、交付创新、经销伙伴和真实世界证据来实现差异化，从而满足癌症疼痛治疗领域尚未满足的需求

随着各公司寻求差异化策略以应对癌症疼痛管理的临床复杂性和支付方需求，竞争格局正在改变。领先的创新企业正将针对非鸦片类药物和辅助性治疗的标靶研究与对新型给药系统的投资相结合，以优化安全性和依从性。同时，学名药和专科製药公司正在扩大依从性支援服务，例如病患教育和护理人员主导的剂量调整方案，同时强调供应可靠性和成本效益。

製药公司与专科药局和家庭输液服务提供者的合作日益重要，有助于简化药品分销流程并支持复杂的给药方案。与科技公司建立策略联盟，能够实现远端监测解决方案，并将真实世界证据纳入价值评估文件，从而加强与支付方的谈判和上市后监测。同时，专注于介入性疼痛技术和局部麻醉剂的公司正与临床卓越中心合作，为手术疼痛管理通讯协定建立实证基础。

在这些方法中，成功的市场参与企业在临床可靠性和卓越营运之间取得平衡，投资于完善的药物监测、供应链透明度和临床医生参与计画。透过展示可衡量的改进，例如改善患者功能、提高用药依从性和减少急诊就诊，企业可以增强其对医疗服务提供者和支付方的价值提案，同时满足癌症相关疼痛管理领域尚未满足的需求。

为领导者提供切实可行的、优先考虑的建议，以加强供应韧性、推进阿片类药物减量疗法，并使商业模式与可衡量的临床结果保持一致。

产业领导者可以透过落实以下几项切实可行的建议，采取果断行动，从而赢得临床信任和商业性优势。首先，应优先考虑供应链多元化和紧急生产伙伴关係，以维持产品供应稳定，同时降低贸易和原材料中断带来的风险。同时，应加速开发和应用非鸦片类药物疗法和辅助疗法，以解决癌症疼痛的神经病变和发炎性成分，并支持减少鸦片类药物使用的临床方案。

第二，我们将把数位化监测和病患报告结局工具纳入治疗路径，以实现剂量自适应调整、早期发现不利事件，并产生真实世界数据以支援基于价值的合约。我们还将提案试点合同，将补偿与功能改善和减少急诊就诊挂钩，并致力于围绕疗效评估建立与支付方的关係。第三，我们将投资临床医生教育和管理项目，为医生提供联合治疗、安全阿片类药物处方和适当干预技术的实用指导。

最后，我们制定了针对特定通路和终端用户环境的商业化和准入计划，确保医院处方集、居家照护机构和专科药房获得支持复杂治疗方案所需的培训和材料。这些建议的实施需要临床、供应链、报销和商业部门之间的跨职能协作，才能将策略转化为患者照护可衡量的改善。

采用严谨的混合调查方法框架，结合专家访谈、文献回顾与真实世界证据。研究限制和伦理保障措施均公开透明。

本分析整合了一项混合方法研究的成果，该研究结合了定性和定量技术，以确保可靠的检验验证。主要研究包括对临床医生、药房主任、医院采购负责人和支付方代表进行结构化访谈，以收集关于临床需求、处方集选择标准和采购趋势的第一手观点。此外，还对同行评审的临床指南、监管公告和政策分析进行了文献综述，以补充这些研究结果，从而更好地理解不断发展的标准和药品管理要求。

本研究利用真实世界证据，包括匿名化的理赔资料和使用模式，评估治疗路径和给药环境，但未提供市场规模资讯。调查方法优先考虑资料质量，透过独立资讯来源间的交叉检验和迭代式同侪审查来实现。对于存在分歧之处，分析明确指出了临床争议或操作不确定性，以帮助决策者确定未来研究的优先顺序。

本调查方法的限制包括不同地区资料可用性的差异、监管环境的变化可能改变临床实务模式，以及各医疗机构通讯协定的异质性。为弥补这些局限性，本研究进行了敏感度分析，并征求了多方相关人员的意见。在研究通讯协定和相关人员中，伦理考量，包括病患隐私和临床资料的合理使用，始终贯穿整个研究流程。

策略结论强调了临床、商业和政策领域之间的合作，突显了将创新转化为可靠的、以患者为中心的癌症疼痛治疗的重要性。

摘要，癌症疼痛管理正处于一个策略转折点，临床创新、政策压力和供应链现实交织在一起，重新定义了疼痛缓解的提供和评估方式。个人化治疗、非鸦片类药物疗法和给药技术的进步为改善病患功能和安全性提供了重要机会，但只有相关人员在治理、实证实践和取得模式方面通力合作，这些成果才能得以实现。不断变化的价格和采购环境进一步凸显了建立具有韧性的供应策略和合约机制以保障医疗服务连续性的必要性。

临床医师的首要任务是整合多模式、以机制为基础的治疗方法，同时利用监测工具来实现个人化治疗。对于製造商和经销商，成功取决于透过真实世界的结果证明产品价值、确保可靠的供应链以及向支付方提出切实可行的提案。对于医疗系统和支付方而言，投资于管理、教育和结果评估对于实现癌症患者永续的高品质疼痛管理至关重要。

最终，将卓越的临床水准、严谨的运作和积极的政策参与相结合的协作方式，对于医学进步至关重要。相关人员，将更有利于改善癌症相关疼痛管理的患者疗效和系统层面的绩效。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将穿戴式感测器技术应用于癌症疼痛的持续监测和管理
  • 药物基因组学分析用于癌症疼痛治疗中的个人化鸦片类药物给药
  • 扩展远端医疗平台，用于远距多学科癌症疼痛咨询和随访
  • 促效剂用于缓解癌症疼痛的非鸦片类週边限制性κ阿片受体激动剂
  • 推动一种先进的鞘内给药系统，该系统具有可程式设计给药功能，用于治疗顽固性癌症疼痛
  • 扩大基于虚拟实境的数位疗法在癌症疼痛管理辅助性治疗的应用
  • 用于治疗神经病变癌痛的大麻素製剂的监管核准和市场上市
  • 整合人工智慧和预测分析技术，优化癌症疼痛治疗路径和疗效

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按药物类别分類的癌症疼痛管理市场

  • 辅助止痛药
    • 抗惊厥药
    • 抗忧郁症
    • 皮质类固醇
  • 局部麻醉剂
  • 非类固醇消炎剂（NSAIDs）
  • 阿片类药物
    • 自然的
    • 半合成
    • 合成

第九章 依给药途径分類的癌症疼痛管理市场

  • 口服
    • 胶囊
    • 解决方案
    • 药片
  • 肠外
    • 肌肉内注射
    • 静脉注射
    • 皮下
  • 舌下给药
    • 电影
    • 锭剂
  • 经皮

第十章 癌症疼痛管理市场依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 按最终用户分類的癌症疼痛管理市场

  • 癌症研究所
  • 居家照护
  • 医院

第十二章 按应用程式分類的癌症疼痛管理市场

  • 骨转移性疼痛
  • 神经病变疼痛
  • 内臟疼痛

第十三章 各地区癌症疼痛管理市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 癌症疼痛管理市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国癌症疼痛管理市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Teva Pharmaceutical Industries Ltd.
    • Johnson & Johnson
    • Pfizer Inc.
    • Viatris Inc.
    • Endo International plc
    • Hikma Pharmaceuticals PLC
    • Grunenthal GmbH
    • Mallinckrodt Pharmaceuticals
    • Purdue Pharma LP
    • Mayne Pharma Group Ltd.
Product Code: MRR-144C638C8F7B

The Cancer Pain Management Market is projected to grow by USD 12.81 billion at a CAGR of 6.29% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.86 billion
Estimated Year [2025] USD 8.35 billion
Forecast Year [2032] USD 12.81 billion
CAGR (%) 6.29%

An authoritative introduction to cancer pain management that frames clinical complexity, multidisciplinary care, and strategic priorities for stakeholders across health systems

Cancer pain management occupies a pivotal intersection between oncology care, palliative medicine, and health system economics. Advances in oncology have extended survival for many patients, which in turn has broadened the need for nuanced, sustained approaches to pain control that preserve function and quality of life. Clinicians now balance acute procedural pain, chronic cancer-related pain syndromes, and complex neuropathic presentations alongside comorbidities, polypharmacy, and diverse patient preferences. Consequently, pain management strategies must be adaptable, evidence-driven, and aligned with evolving standards of care.

Across care settings, the imperative is to deliver targeted analgesia while minimizing adverse effects and dependence risks. This requires integration of pharmacologic options spanning adjuvant analgesics, local anesthetics, nonsteroidal anti-inflammatory drugs, and opioid therapies with nonpharmacologic modalities and interventional techniques. Regulatory frameworks, public health priorities on opioid stewardship, and payer policies are reshaping provider decision-making. Moreover, patient-centered models that incorporate shared decision-making and outcomes measurement are becoming central to defining value in therapy selection.

Given these complexities, stakeholders need consolidated, clinically rigorous guidance that synthesizes therapeutic modalities, route-of-administration considerations, distribution dynamics, and end-user requirements. This executive summary distills strategic insights and practical recommendations designed to inform clinical leaders, product strategists, and health systems as they adapt to a rapidly changing therapeutic landscape for cancer-associated pain.

How clinical personalization, opioid stewardship, new delivery technologies, and payer-driven outcomes are reshaping cancer pain management across care pathways

The landscape of cancer pain management is undergoing several transformative shifts that collectively reorient clinical practice and commercial strategy. First, there is a measurable move toward personalized analgesic regimens driven by improved phenotyping of pain subtypes and a clearer understanding of neuropathic versus nociceptive mechanisms. This shift is encouraging clinicians to select therapies based on pain etiology and patient-specific risk factors rather than a one-size-fits-all algorithm.

Simultaneously, opioid stewardship initiatives and heightened scrutiny of opioid prescribing are accelerating adoption of multimodal approaches that emphasize adjuvant analgesics, regional techniques, and targeted non-opioid pharmacotherapies. These changes are compounded by the emergence of novel delivery platforms and transdermal systems that improve adherence and minimize systemic exposure. Digital therapeutics, remote monitoring, and telemedicine are further altering care pathways by enabling continuous assessment of pain, side effects, and patient-reported outcomes, which supports more responsive titration of therapy.

On the commercial front, supply chain resilience and strategic partnerships between specialty pharmacies, hospital procurement teams, and manufacturers are reshaping distribution. Payers are increasingly focused on outcomes and cost-containment, prompting new contracting models that reward improved functional outcomes and reduced hospitalization. Taken together, these shifts call for adaptive clinical protocols, investment in data-driven monitoring, and collaborative policy engagement to ensure patients receive effective, safe, and accessible pain care.

Assessing the multifaceted operational and procurement consequences of 2025 United States tariff measures on availability and access to cancer pain therapeutics

Policy and trade measures enacted in 2025 have introduced new dynamics that influence procurement, pricing behavior, and supply chain planning for cancer pain therapeutics. Tariff adjustments affecting imported active pharmaceutical ingredients and finished dosage forms have increased the complexity of sourcing decisions for manufacturers and health systems. Many stakeholders have responded by reassessing supplier portfolios and accelerating strategies to diversify manufacturing and raw-material sourcing to mitigate exposure to tariff-driven cost pressures.

For hospital systems and pharmacy networks that manage formularies and procurement, the cumulative effect has been a sharper focus on total cost of care. Procurement teams are negotiating longer-term supply agreements, seeking contractual protections against price volatility, and prioritizing suppliers with vertically integrated capabilities. In parallel, some manufacturers have evaluated onshore or nearshore manufacturing options and strategic partnerships to preserve market access and reduce vulnerability to future trade uncertainties.

These developments also elevate the importance of transparent pricing arrangements and value-based contracting that align payment with measurable clinical outcomes. Clinicians and pharmacy leaders are adapting by emphasizing clinical pathways that demonstrate cost-effectiveness, promoting therapeutic alternatives where clinically appropriate, and engaging with payers to ensure continuity of access for patients with the most significant needs. Ultimately, ongoing policy monitoring and proactive supply chain strategies will be essential to sustaining reliable access to cancer pain medications in a more tariff-sensitive environment.

Detailed segmentation insights that illuminate product positioning, clinical pathway alignment, and distribution differentiation across drug classes, routes, channels, users, and applications

A segmentation-driven analysis reveals differentiated clinical and commercial dynamics across drug classes, routes of administration, distribution channels, end-user settings, and application-specific needs. Based on drug class, the landscape encompasses adjuvant analgesics, local anesthetics, nonsteroidal anti-inflammatory drugs, and opioids. Within adjuvant analgesics, specific subgroups such as anticonvulsants, antidepressants, and corticosteroids address neuropathic and inflammatory components of cancer pain, while opioids are further categorized into natural, semi-synthetic, and synthetic agents that vary in receptor profiles, safety considerations, and regulatory oversight.

Route of administration is another critical axis of differentiation, with oral, parenteral, sublingual, and transdermal options shaping real-world use. Oral therapies are commonly delivered as capsules, solutions, or tablets and remain central to chronic outpatient management, whereas parenteral formulations-delivered intramuscularly, intravenously, or subcutaneously-are essential for acute, procedural, or inpatient care. Sublingual modalities, including films and lozenges, provide rapid onset and convenience for breakthrough pain, and transdermal systems support sustained delivery with adherence advantages in select populations.

Distribution channel nuances inform access and patient experience through hospital pharmacy, online pharmacy, and retail pharmacy pathways, each of which has distinct procurement, dispensing, and stewardship workflows. End-user segmentation spans cancer institutes, home care environments, and hospitals, which differ in clinical expertise, monitoring capabilities, and resource intensity. Finally, application-specific considerations-such as bone metastasis pain, neuropathic pain, and visceral pain-require tailored analgesic strategies and care pathways. Together, these segmentation lenses guide product positioning, clinical guideline development, and targeted stakeholder engagement to meet varied clinical needs and operational realities.

A regional analysis of access models, prescribing practices, and supply chain implications across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics exert powerful influence on access models, therapeutic preferences, and stakeholder priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated delivery systems and a strong specialty pharmacy footprint emphasize rapid adoption of novel delivery platforms and patient support programs, while regulatory focus on opioid safety continues to shape prescribing norms and stewardship initiatives. Contrastively, Europe, Middle East & Africa present a mosaic of payer structures and procurement arrangements, where centralized tendering in some markets coexists with highly localized formularies and differing palliative care infrastructures.

Asia-Pacific markets show marked heterogeneity in infrastructure maturity, with some urban centers adopting advanced multimodal pain management pathways and telemedicine-enabled follow-up, while other areas contend with fragmented access and supply chain constraints. Across all regions, demographic trends and rising survivorship are increasing demand for sustained, patient-centered pain management solutions, but the pathways to access differ based on reimbursement models, local regulatory priorities, and the prevalence of community-based versus hospital-centric care.

Transitioning from regional characteristics to operational implications, stakeholders must tailor clinical education, distribution partnerships, and evidence generation strategies to regional payer expectations and regulatory frameworks. By aligning product dossiers and value narratives with region-specific care models and procurement mechanisms, manufacturers and health systems can better support clinicians and patients within each distinct regional context.

How leading companies are differentiating through R&D, delivery innovation, distribution partnerships, and real-world evidence to address the unmet needs in cancer pain care

Competitive dynamics are evolving as companies pursue differentiated strategies to address clinical complexity and payer demands in cancer pain management. Leading innovators are combining targeted research into non-opioid and adjuvant therapies with investments in novel delivery systems that optimize safety and adherence. In parallel, generic and specialty manufacturers are emphasizing supply reliability and cost-efficiency while expanding services that support adherence, such as patient education and nurse-led titration programs.

Partnerships between pharmaceutical companies and specialty pharmacies or home infusion providers are becoming increasingly important to streamline distribution and support complex dosing regimens. Strategic alliances with technology firms are enabling remote monitoring solutions that feed real-world evidence into value dossiers, strengthening payer negotiations and post-market surveillance. Meanwhile, companies focused on interventional pain technologies and regional anesthetic agents are aligning with clinical centers of excellence to build evidence for procedural pain management protocols.

Across these approaches, successful market participants balance clinical credibility with operational excellence, investing in robust pharmacovigilance, supply chain transparency, and clinician engagement programs. By demonstrating measurable improvements in patient function, adherence, and reduced acute care utilization, companies can strengthen their value proposition to providers and payers while addressing unmet needs in cancer-associated pain management.

Practical and prioritized recommendations for leaders to strengthen supply resilience, advance opioid-sparing therapies, and align commercial models with measurable clinical outcomes

Industry leaders can act decisively to capture clinical trust and commercial advantage by operationalizing several pragmatic recommendations. First, prioritize diversification of supply chains and contingency manufacturing partnerships to reduce exposure to trade and raw-material disruptions while maintaining consistent product availability. At the same time, accelerate development and adoption of non-opioid therapeutics and adjuvant agents that address neuropathic and inflammatory components of cancer pain, thereby supporting opioid-sparing clinical algorithms.

Second, embed digital monitoring and patient-reported outcome tools into care pathways to enable responsive titration, detect adverse events earlier, and generate real-world data that supports value-based contracting. Concurrently, cultivate payer relationships around outcomes measurement by proposing pilot agreements that align reimbursement with functional gains and reductions in acute care utilization. Third, invest in clinician education and stewardship programs that provide practical guidance for multimodal regimens, safe opioid prescribing, and interventional techniques where appropriate.

Finally, tailor commercialization and access plans to the nuances of distribution channels and end-user settings; for example, ensure hospital formularies, home care providers, and specialty pharmacies have the training and materials needed to support complex regimens. Operationalizing these recommendations will require cross-functional collaboration among clinical affairs, supply chain, reimbursement, and commercial teams to translate strategy into measurable improvements in patient care.

A rigorous mixed-methods research framework combining expert interviews, literature synthesis, and real-world evidence with transparency on limitations and ethical safeguards

This analysis synthesizes findings derived from a mixed-methods research approach combining qualitative and quantitative techniques to ensure robust triangulation. Primary research included structured interviews with clinicians, pharmacy leaders, hospital procurement officers, and payer representatives to capture frontline perspectives on clinical needs, formulary decision criteria, and procurement dynamics. These insights were complemented by secondary literature reviews of peer-reviewed clinical guidelines, regulatory announcements, and policy analyses to contextualize evolving standards and stewardship imperatives.

Real-world evidence sources, including anonymized claims and utilization patterns, informed assessments of treatment pathways and administration settings without providing market sizing. The methodology prioritized data quality through cross-validation across independent sources and iterative expert review. Where divergent viewpoints emerged, the analysis explicitly flagged areas of clinical debate and operational uncertainty to aid decision-makers in prioritizing further inquiry.

Limitations of the methodology include variability in regional data availability, evolving regulatory landscapes that may change practice patterns, and heterogeneity in institutional protocols. To mitigate these limitations, the research incorporated sensitivity checks and sought corroboration from multiple stakeholders. Ethical considerations, including patient privacy and responsible use of clinical data, guided the research protocols and stakeholder engagements throughout the study.

A strategic conclusion emphasizing collaboration across clinical, commercial, and policy domains to translate innovation into reliable, patient-centered cancer pain care

In summary, cancer pain management is at a strategic inflection point where clinical innovation, policy pressures, and supply chain realities intersect to redefine how analgesia is delivered and valued. Advances in personalized approaches, non-opioid therapies, and delivery technologies offer meaningful opportunities to improve patient function and safety, but these gains will only be realized if stakeholders align on stewardship, evidence generation, and access models. The evolving tariff and procurement environment further underscore the need for resilient supply strategies and contracting mechanisms that protect continuity of care.

For clinicians, the priority is to integrate multimodal, mechanism-based regimens while leveraging monitoring tools to individualize treatment. For manufacturers and distributors, success depends on demonstrating value through real-world outcomes, securing reliable supply pathways, and engaging payers with pragmatic propositions. For health systems and payers, investments in stewardship, education, and outcome measurement will be critical to achieving sustainable, high-quality pain management for patients with cancer.

Ultimately, a collaborative approach that links clinical excellence with operational rigor and policy engagement will be essential to advance care. Stakeholders who act deliberately-balancing innovation with pragmatic supply and reimbursement strategies-will be best positioned to improve patient outcomes and system-level performance in cancer-related pain management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of wearable sensor technology for continuous cancer pain monitoring and management
  • 5.2. Adoption of pharmacogenomic profiling to personalize opioid dosing in cancer pain treatment
  • 5.3. Expansion of telemedicine platforms for remote multidisciplinary cancer pain consultations and follow up
  • 5.4. Development of non opioid peripherally restricted kappa opioid receptor agonists for cancer pain relief
  • 5.5. Emergence of advanced intrathecal drug delivery systems with programmable dosing for refractory cancer pain
  • 5.6. Increasing use of virtual reality based digital therapeutics as adjuncts for cancer pain management
  • 5.7. Regulatory approval and market uptake of cannabinoid based formulations targeting neuropathic cancer pain
  • 5.8. Integration of artificial intelligence predictive analytics to optimize cancer pain treatment pathways and outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Pain Management Market, by Drug Class

  • 8.1. Adjuvant Analgesics
    • 8.1.1. Anticonvulsants
    • 8.1.2. Antidepressants
    • 8.1.3. Corticosteroids
  • 8.2. Local Anesthetics
  • 8.3. Nsaids
  • 8.4. Opioids
    • 8.4.1. Natural
    • 8.4.2. Semi-Synthetic
    • 8.4.3. Synthetic

9. Cancer Pain Management Market, by Route Of Administration

  • 9.1. Oral
    • 9.1.1. Capsules
    • 9.1.2. Solutions
    • 9.1.3. Tablets
  • 9.2. Parenteral
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
    • 9.2.3. Subcutaneous
  • 9.3. Sublingual
    • 9.3.1. Films
    • 9.3.2. Lozenges
  • 9.4. Transdermal

10. Cancer Pain Management Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Cancer Pain Management Market, by End User

  • 11.1. Cancer Institutes
  • 11.2. Home Care
  • 11.3. Hospitals

12. Cancer Pain Management Market, by Application

  • 12.1. Bone Metastasis Pain
  • 12.2. Neuropathic Pain
  • 12.3. Visceral Pain

13. Cancer Pain Management Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Pain Management Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Pain Management Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Teva Pharmaceutical Industries Ltd.
    • 16.3.2. Johnson & Johnson
    • 16.3.3. Pfizer Inc.
    • 16.3.4. Viatris Inc.
    • 16.3.5. Endo International plc
    • 16.3.6. Hikma Pharmaceuticals PLC
    • 16.3.7. Grunenthal GmbH
    • 16.3.8. Mallinckrodt Pharmaceuticals
    • 16.3.9. Purdue Pharma L.P.
    • 16.3.10. Mayne Pharma Group Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CANCER PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CANCER PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER PAIN MANAGEMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NSAIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NATURAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NATURAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NATURAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NATURAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NATURAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SEMI-SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SEMI-SYNTHETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SEMI-SYNTHETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SEMI-SYNTHETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SEMI-SYNTHETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SEMI-SYNTHETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SYNTHETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SYNTHETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FILMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FILMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FILMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FILMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FILMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FILMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOZENGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOZENGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOZENGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOZENGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOZENGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LOZENGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CANCER INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CANCER INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CANCER INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY CANCER INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BONE METASTASIS PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BONE METASTASIS PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BONE METASTASIS PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BONE METASTASIS PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BONE METASTASIS PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BONE METASTASIS PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY VISCERAL PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY VISCERAL PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY VISCERAL PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY VISCERAL PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY VISCERAL PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY VISCERAL PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY ADJUVANT ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY SUBLINGUAL, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE CANCER PAIN MANAGEMENT MARKET SIZE, BY DIS